Credit Suisse’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Credit Suisse’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,454	Closed	-$456K	–	4356
2016 Q3	$456K	Buy	+11,454	New	+$128K	﹤0.01%	3466
2015 Q1	–	Sell	-4,065	Closed	-$33K	–	4732
2014 Q4	$33K	Buy	4,065 +2,833	+230%	+$24.4K	﹤0.01%	4533
2014 Q3	$12K	Buy	+1,232	New	+$24.3K	﹤0.01%	4405
2014 Q2	–	Sell	-3,711	Closed	-$418K	–	4923
2014 Q1	$418K	Buy	+3,711	New	+$260K	﹤0.01%	3851

Credit Suisse's TBRA Position: Q4 2016 in Review

Credit Suisse sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 11,454 shares — an estimated $456K sold.

Credit Suisse first reported a position in TBRA in Q1 2014 and held it in 4 quarters. The position peaked at $456K in Q3 2016. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.

Credit Suisse reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Credit Suisse sold 11,454 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $456K.
Credit Suisse first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2014 and held it in 4 quarters.
Credit Suisse's Tobira Therapeutics, Inc. Common Stock position peaked at $456K in Q3 2016.
0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.